CA3119720A1 - Engineered extracellular vesicles and uses thereof - Google Patents

Engineered extracellular vesicles and uses thereof Download PDF

Info

Publication number
CA3119720A1
CA3119720A1 CA3119720A CA3119720A CA3119720A1 CA 3119720 A1 CA3119720 A1 CA 3119720A1 CA 3119720 A CA3119720 A CA 3119720A CA 3119720 A CA3119720 A CA 3119720A CA 3119720 A1 CA3119720 A1 CA 3119720A1
Authority
CA
Canada
Prior art keywords
protein
seq
amino acid
exosome
scaffold protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3119720A
Other languages
English (en)
French (fr)
Inventor
Kevin P. Dooley
Rane A. Harrison
Ke Xu
Damian J. Houde
Sonya Haupt
John D. KULMAN
Douglas E. Williams
Russell E. Mcconnell
Madeleine YOUNISS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Sales AG
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70732111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3119720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2018/061679 external-priority patent/WO2019099942A1/en
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of CA3119720A1 publication Critical patent/CA3119720A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3119720A 2018-11-16 2019-05-22 Engineered extracellular vesicles and uses thereof Pending CA3119720A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US2018/061679 2018-11-16
PCT/US2018/061679 WO2019099942A1 (en) 2017-11-17 2018-11-16 Compositions of engineered exosomes and methods of loading luminal exosomes payloads
US201962835430P 2019-04-17 2019-04-17
US62/835,430 2019-04-17
PCT/US2019/033629 WO2020101740A1 (en) 2018-11-16 2019-05-22 Engineered extracellular vesicles and uses thereof

Publications (1)

Publication Number Publication Date
CA3119720A1 true CA3119720A1 (en) 2020-05-22

Family

ID=70732111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3119720A Pending CA3119720A1 (en) 2018-11-16 2019-05-22 Engineered extracellular vesicles and uses thereof

Country Status (28)

Country Link
EP (3) EP4059510B1 (https=)
JP (2) JP7538795B2 (https=)
KR (1) KR20210098473A (https=)
CN (2) CN113286603B (https=)
AU (1) AU2019378591A1 (https=)
BR (1) BR112021009231A2 (https=)
CA (1) CA3119720A1 (https=)
CL (1) CL2021001278A1 (https=)
CY (1) CY1124897T1 (https=)
DK (1) DK3672614T3 (https=)
EA (1) EA202191334A1 (https=)
ES (1) ES2907967T3 (https=)
HR (1) HRP20220020T1 (https=)
HU (1) HUE057300T2 (https=)
IL (1) IL283167A (https=)
LT (1) LT3672614T (https=)
MA (1) MA49971B1 (https=)
MD (1) MD3672614T2 (https=)
MX (1) MX2021005636A (https=)
PH (1) PH12021551088A1 (https=)
PL (1) PL3672614T3 (https=)
PT (1) PT3672614T (https=)
RS (1) RS62863B1 (https=)
SG (1) SG11202104956QA (https=)
SI (1) SI3672614T1 (https=)
SM (1) SMT202200156T1 (https=)
TW (2) TWI846697B (https=)
WO (1) WO2020101740A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111290WA (en) * 2019-04-17 2021-11-29 Codiak Biosciences Inc Compositions of exosomes and aav
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
KR20220070433A (ko) * 2019-08-14 2022-05-31 코디악 바이오사이언시즈, 인크. Stat6을 표적으로 하는 세포외 소포-aso 작제물
CA3147366A1 (en) 2019-08-14 2021-02-18 Adam T. BOUTIN Extracellular vesicles with stat3-antisense oligonucleotides
CA3147701A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
AU2020330133A1 (en) * 2019-08-14 2022-03-17 Lonza Sales Ag Extracellular vesicle-ASO constructs targeting CEBP/beta
MX2022003570A (es) 2019-09-25 2022-07-11 Codiak Biosciences Inc Composiciones de vesícula extracelular.
KR20220094221A (ko) 2019-09-25 2022-07-05 코디악 바이오사이언시즈, 인크. 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
WO2021062057A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Exogenous loading of exosomes via lyophilization
WO2021062058A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
KR20210116324A (ko) 2020-03-12 2021-09-27 기초과학연구원 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
WO2022032140A2 (en) * 2020-08-07 2022-02-10 Amicus Therapeutics, Inc. Vesicle targeting proteins and uses of same
CA3193107A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
GB202015399D0 (en) * 2020-09-29 2020-11-11 Evox Therapeutics Ltd Engineered extracellular vesicles displaying enhanced pharmacokinetics
US20230364127A1 (en) 2020-10-06 2023-11-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
CN112899307A (zh) * 2021-01-28 2021-06-04 苏州大学 GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用
JP2024506712A (ja) 2021-02-17 2024-02-14 ロンザ セールス アーゲー 細胞外ベシクルを負荷する方法
CA3207944A1 (en) * 2021-02-17 2022-08-25 Ajay Verma Extracellular vesicle-nlrp3 antagonist
KR20230166101A (ko) 2021-04-01 2023-12-06 론자 세일즈 아게 세포외 소포 조성물
CN114057893B (zh) * 2021-04-26 2022-12-30 苏州大学 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用
CN117126886A (zh) * 2022-05-20 2023-11-28 谛邈生物科技(北京)有限公司 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用
KR102788272B1 (ko) * 2022-05-24 2025-04-01 주식회사 시프트바이오 표면-개질된 세포외 소포체 및 이의 치료학적 용도
WO2024215711A1 (en) * 2023-04-10 2024-10-17 Wake Forest University Health Sciences Modified mammalian vesicles and compositions and methods related thereto
CN116769718A (zh) * 2023-04-21 2023-09-19 南京逸微健华生物科技有限公司 一种工程化细胞外囊泡及用途
WO2024226723A1 (en) * 2023-04-26 2024-10-31 Northwestern University Active loading of biomolecular cargo into engineered vesicles
CN118909084A (zh) * 2023-05-08 2024-11-08 天津外泌体科技有限公司 细胞外囊泡支架蛋白及其应用
EP4644537A1 (en) 2024-04-30 2025-11-05 ConvEyXo Targeted extracellular vesicle
WO2025232431A1 (zh) * 2024-05-08 2025-11-13 天津外泌体科技有限公司 筛选影响细胞外囊泡被摄取的基因的系统和方法
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP2254586B1 (en) * 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
FR2950350B1 (fr) 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
EP3397264A4 (en) * 2015-12-30 2019-06-05 The Regents of The University of California METHOD FOR IMPROVED PREPARATION AND INSULATION OF CELL-DERIVED VESICLES
US10617768B2 (en) * 2016-07-12 2020-04-14 Santa Clara University Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins
US20210290556A1 (en) * 2016-08-22 2021-09-23 Codiak Biosciences, Inc. Methods of suppressing delivery of exosomes to liver and spleen
US20200025685A1 (en) * 2016-12-15 2020-01-23 Codiak Biosciences, Inc. Methods of measuring exosomes using intrinsic fluorescence
IL272786B2 (en) 2017-08-25 2025-03-01 Codiak Biosciences Inc Preparation of therapeutic exosomes using membrane proteins
WO2019099942A1 (en) * 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of engineered exosomes and methods of loading luminal exosomes payloads
EP3841112A1 (en) * 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof

Also Published As

Publication number Publication date
JP2022513049A (ja) 2022-02-07
AU2019378591A1 (en) 2021-06-17
TW202438105A (zh) 2024-10-01
EP4628099A2 (en) 2025-10-08
TW202038993A (zh) 2020-11-01
WO2020101740A1 (en) 2020-05-22
WO2020101740A9 (en) 2021-06-10
EA202191334A1 (ru) 2022-02-10
HRP20220020T1 (hr) 2022-04-01
EP4628099A3 (en) 2025-11-19
MA49971A (fr) 2020-07-01
PH12021551088A1 (en) 2022-01-03
SMT202200156T1 (it) 2022-05-12
SG11202104956QA (en) 2021-06-29
EP4059510B1 (en) 2025-05-21
EP4059510A1 (en) 2022-09-21
ES2907967T3 (es) 2022-04-27
DK3672614T3 (da) 2022-01-10
CY1124897T1 (el) 2023-01-05
MA49971B1 (fr) 2022-01-31
IL283167A (en) 2021-06-30
EP3672614A1 (en) 2020-07-01
EP3672614B1 (en) 2021-10-06
PT3672614T (pt) 2022-02-11
MD3672614T2 (ro) 2022-04-30
RS62863B1 (sr) 2022-02-28
CN113286603A (zh) 2021-08-20
CN113286603B (zh) 2025-07-22
JP7538795B2 (ja) 2024-08-22
SI3672614T1 (sl) 2022-04-29
EP4059510C0 (en) 2025-05-21
CN121102502A (zh) 2025-12-12
CL2021001278A1 (es) 2022-03-11
JP2024097929A (ja) 2024-07-19
LT3672614T (lt) 2022-04-11
BR112021009231A2 (pt) 2021-08-10
KR20210098473A (ko) 2021-08-10
MX2021005636A (es) 2021-07-06
TWI846697B (zh) 2024-07-01
HUE057300T2 (hu) 2022-05-28
PL3672614T3 (pl) 2022-03-07

Similar Documents

Publication Publication Date Title
EP4059510B1 (en) Engineered extracellular vesicles and uses thereof
TW202100164A (zh) 用於疫苗遞送之細胞外囊泡
US20230323401A1 (en) Methods and compositions for genome editing
US20220251200A1 (en) Extracellular vesicles targeting t cells and uses thereof
WO2020041720A1 (en) Extracellular vesicles targeting dendritic cells and uses thereof
US20200208177A1 (en) Methods and compositions for genome editing
US20220017907A1 (en) Engineered extracellular vesicles and uses thereof
US20250249072A1 (en) Methods of treating cancer
HK40032716B (en) Engineered extracellular vesicles and uses thereof
HK40032716A (en) Engineered extracellular vesicles and uses thereof
US20220218811A1 (en) Methods of treating tuberculosis
WO2021003425A1 (en) Methods of inducing hematopoiesis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220908

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250522

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260112